Rui Kitadai

501 total citations
27 papers, 296 citations indexed

About

Rui Kitadai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Rui Kitadai has authored 27 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Rui Kitadai's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (6 papers). Rui Kitadai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (6 papers). Rui Kitadai collaborates with scholars based in Japan, United States and United Kingdom. Rui Kitadai's co-authors include Yusuke Okuma, Yukio Hosomi, Taiki Hakozaki, Shingo Kitagawa, Jumpei Kashima, Akihiro Shimizu, Kan Yonemori, Tadaaki Nishikawa, Tatsunori Shimoi and Kazuki Sudo and has published in prestigious journals such as Cancer Research, European Journal of Cancer and Gynecologic Oncology.

In The Last Decade

Rui Kitadai

22 papers receiving 293 citations

Peers

Rui Kitadai
M. Martín Jiménez Spain
Huiping Qiang China
Şeyda Gündüz Türkiye
Qing Chang China
Benjamin Bonhomme France
Yvonne Ang Singapore
Maria Antista Italy
Sarah Caulfield United States
И. А. Покатаев Russia
Zhangzhou Huang China
M. Martín Jiménez Spain
Rui Kitadai
Citations per year, relative to Rui Kitadai Rui Kitadai (= 1×) peers M. Martín Jiménez

Countries citing papers authored by Rui Kitadai

Since Specialization
Citations

This map shows the geographic impact of Rui Kitadai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rui Kitadai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rui Kitadai more than expected).

Fields of papers citing papers by Rui Kitadai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rui Kitadai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rui Kitadai. The network helps show where Rui Kitadai may publish in the future.

Co-authorship network of co-authors of Rui Kitadai

This figure shows the co-authorship network connecting the top 25 collaborators of Rui Kitadai. A scholar is included among the top collaborators of Rui Kitadai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rui Kitadai. Rui Kitadai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kitadai, Rui, Yusuke Okuma, Taro Shibata, Takashi Kohno, & Takafumi Koyama. (2025). Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository. European Journal of Cancer. 220. 115380–115380.
2.
3.
Kojima, Yuki, Hiroshi Yoshida, Rui Kitadai, et al.. (2024). Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer. International Journal of Gynecological Pathology. 44(2). 104–111. 3 indexed citations
4.
Shimoi, Tatsunori, Yuki Kojima, T. Yamanaka, et al.. (2024). Abstract PO3-15-12: Expression and co-expression patterns of TROP2 and HER2 in breast cancer: implications for bispecific antibody-drug conjugate therapy. Cancer Research. 84(9_Supplement). PO3–15. 2 indexed citations
5.
Kojima, Yuki, Hiroshi Yoshida, Rui Kitadai, et al.. (2024). Trop-2 expression and the tumor immune microenvironment in cervical cancer. Gynecologic Oncology. 187. 51–57. 10 indexed citations
6.
Kitadai, Rui, Tatsunori Shimoi, Hitomi Sumiyoshi Okuma, et al.. (2024). Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast Cancer. 31(6). 1037–1045. 2 indexed citations
7.
Saito, Ayumi, Tadaaki Nishikawa, Hiroshi Yoshida, et al.. (2023). Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. Gynecologic Oncology. 176. 115–121. 10 indexed citations
8.
Kojima, Yuki, Hiroshi Yoshida, Rui Kitadai, et al.. (2022). High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. Journal of Gynecologic Oncology. 33(6). e82–e82. 8 indexed citations
9.
Hakozaki, Taiki, Rui Kitadai, Kosuke Narita, et al.. (2022). Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Translational Lung Cancer Research. 11(2). 135–149. 10 indexed citations
10.
Kitadai, Rui, Tatsunori Shimoi, Kazuki Sudo, et al.. (2021). Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. BMC Cancer. 21(1). 294–294. 6 indexed citations
11.
Yazaki, Shu, Yuki Kojima, Hiroshi Yoshida, et al.. (2021). Abstract 657: Folate receptor alpha expression is associated with poor prognosis in patients with cervical cancer. Cancer Research. 81(13_Supplement). 657–657. 3 indexed citations
12.
Hakozaki, Taiki, et al.. (2020). Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy. Journal of Cancer Research and Clinical Oncology. 146(10). 2659–2668. 23 indexed citations
13.
Watanabe, Kageaki, Rui Kitadai, Shingo Kitagawa, Takashi Toya, & Yukio Hosomi. (2020). Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin. JTO Clinical and Research Reports. 1(3). 100046–100046. 3 indexed citations
14.
Hakozaki, Taiki, Yukio Hosomi, Rui Kitadai, Shingo Kitagawa, & Yusuke Okuma. (2020). Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 146(11). 2957–2966. 13 indexed citations
15.
Yoshimura, Akihiro, Tadaaki Yamada, Yusuke Okuma, et al.. (2019). Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Translational Lung Cancer Research. 8(4). 450–460. 22 indexed citations
16.
Kitadai, Rui, Yusuke Okuma, & Jumpei Kashima. (2019). Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer. Case Reports in Oncology. 12(1). 171–177. 1 indexed citations
17.
Kitadai, Rui, et al.. (2019). Lateral Uveitis Induced by Pembrolizumab in Patients with Non-small Cell Lung Cancer: a Case Report. Haigan. 59(3). 265–269. 1 indexed citations
18.
Kashima, Jumpei, Rui Kitadai, & Yusuke Okuma. (2019). Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists. Cancers. 11(5). 599–599. 42 indexed citations
19.
Kitadai, Rui, Yusuke Okuma, Taiki Hakozaki, & Yukio Hosomi. (2019). The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. Journal of Cancer Research and Clinical Oncology. 146(3). 777–785. 49 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Martín Jiménez Breakdown of academic impact, for papers by Huiping Qiang Breakdown of academic impact, for papers by Şeyda Gündüz Breakdown of academic impact, for papers by Qing Chang Breakdown of academic impact, for papers by Benjamin Bonhomme Breakdown of academic impact, for papers by Yvonne Ang Breakdown of academic impact, for papers by Maria Antista Breakdown of academic impact, for papers by Sarah Caulfield Breakdown of academic impact, for papers by И. А. Покатаев Breakdown of academic impact, for papers by Zhangzhou Huang
Rankless by CCL
2026